BRADY CORP Quarterly Deferred Income Tax Expense (Benefit) in USD from Q3 2010 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Brady Corp annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q3 2010 to Q3 2023.
  • Brady Corp Deferred Income Tax Expense (Benefit) for the quarter ending October 31, 2023 was -$2.23M, a 30.5% decline year-over-year.
  • Brady Corp annual Deferred Income Tax Expense (Benefit) for 2024 was -$9.4M, a 24.6% increase from 2023.
  • Brady Corp annual Deferred Income Tax Expense (Benefit) for 2023 was -$12.5M, a 658% decline from 2022.
  • Brady Corp annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.65M, a 81.7% increase from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$2.23M -$520K -30.5% Aug 1, 2023 Oct 31, 2023 10-Q 2023-11-16
Q3 2022 -$1.71M -$1.08M -173% Aug 1, 2022 Oct 31, 2022 10-Q 2023-11-16
Q3 2021 -$625K +$550K +46.8% Aug 1, 2021 Oct 31, 2021 10-Q 2022-11-17
Q3 2020 -$1.18M -$2.18M -216% Aug 1, 2020 Oct 31, 2020 10-Q 2021-11-18
Q3 2019 $1.01M -$1.16M -53.4% Aug 1, 2019 Oct 31, 2019 10-Q 2020-11-19
Q3 2018 $2.16M +$3.33M Aug 1, 2018 Oct 31, 2018 10-Q 2019-11-21
Q3 2017 -$1.17M -$3.2M -158% Aug 1, 2017 Oct 31, 2017 10-Q 2018-11-15
Q3 2016 $2.03M +$1.3M +179% Aug 1, 2016 Oct 31, 2016 10-Q 2017-11-16
Q3 2015 $726K -$1.62M -69.1% Aug 1, 2015 Oct 31, 2015 10-Q 2016-11-16
Q3 2014 $2.35M +$4.77M Aug 1, 2014 Oct 31, 2014 10-Q 2015-11-19
Q3 2013 -$2.42M -$2.31M -2121% Aug 1, 2013 Oct 31, 2013 10-Q 2014-12-02
Q3 2012 -$109K -$4.51M -102% Aug 1, 2012 Oct 31, 2012 10-Q 2013-12-06
Q3 2011 $4.4M +$9.25M Aug 1, 2011 Oct 31, 2011 10-Q 2012-12-05
Q3 2010 -$4.85M Aug 1, 2010 Oct 31, 2010 10-Q 2011-12-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.